Want to see GRCE full AI Analyst Report?
Top Page
Grace Therapeutics
(NASDAQ:GRCE)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▼(-14.16% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and a bearish technical trend (below key moving averages with negative MACD). A recent capital raise that extends runway provides a meaningful but secondary positive offset, while valuation is difficult to justify with negative earnings and no dividend yield.
Positive Factors
Low Financial Leverage
A debt-free balance sheet limits interest obligations and reduces refinancing pressure while the company advances its pipeline. This provides greater flexibility to direct available capital toward development, manufacturing, and regulatory work.
Negative Factors
No Commercial Revenue
The absence of revenue confirms that GRCE remains pre-commercial and dependent on successful development and approval of its pipeline. Material recurring losses leave no operating proof of demand, pricing power, or commercial profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
A debt-free balance sheet limits interest obligations and reduces refinancing pressure while the company advances its pipeline. This provides greater flexibility to direct available capital toward development, manufacturing, and regulatory work.
Read all positive factors
Grace Therapeutics (GRCE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.02M
Dividend YieldN/A
Average Volume (3M)58.56K
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue GrowthN/A
EPS Growth-43.60%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.26
Shares Outstanding21,035,930
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.20
Price to Sales (P/S)0.00
P/FCF Ratio-8.62
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside71.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Grace Therapeutics Business Overview & Revenue Model
Company Description
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is G...
How the Company Makes Money
null...
Grace Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -25.68M | -11.07M | -23.74M | -15.37M | -24.51M | -19.17M |
| Net Income | -21.45M | -7.79M | -13.63M | -17.44M | -57.39M | -12.27M |
Balance Sheet | ||||||
| Total Assets | 50.07M | 66.65M | 71.99M | 73.30M | 79.12M | 128.62M |
| Cash, Cash Equivalents and Short-Term Investments | 13.76M | 16.98M | 22.13M | 23.00M | 27.89M | 43.66M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 485.00K | 295.00K |
| Total Liabilities | 1.86M | 2.76M | 5.38M | 11.56M | 11.17M | 20.35M |
| Stockholders Equity | 48.21M | 63.90M | 66.61M | 61.74M | 67.95M | 108.27M |
Cash Flow | ||||||
| Free Cash Flow | -10.30M | -8.87M | -14.90M | -12.36M | -15.93M | -17.23M |
| Operating Cash Flow | -10.30M | -8.87M | -14.90M | -12.33M | -15.91M | -17.23M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 104.00K | 13.15M | -3.52M |
| Financing Cash Flow | 4.04M | 3.71M | 14.03M | 7.36M | 304.00K | 0.00 |
Grace Therapeutics Technical Analysis
Positive
2.33
Price Trends
2.28
Negative
2.60
Negative
3.12
Negative
Market Momentum
-0.04
Negative
49.85
Neutral
69.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Positive. The current price of 2.33 is above the 20-day moving average (MA) of 2.14, above the 50-day MA of 2.28, and below the 200-day MA of 3.12, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 49.85 is Neutral, neither overbought nor oversold. The STOCH value of 69.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRCE.
Grace Therapeutics Risk Analysis
Grace Therapeutics disclosed 53 risk factors in its most recent earnings report. Grace Therapeutics reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Grace Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $96.94M | -3.45 | -311.07% | ― | ― | 61.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $59.30M | -5.10 | 83.45% | ― | ― | 15.65% | |
47 Neutral | $45.02M | -1.75 | -35.78% | ― | ― | -43.60% | |
45 Neutral | $5.67M | -0.33 | -333.32% | ― | ― | 44.80% | |
40 Underperform | $40.21M | -0.91 | -160.72% | ― | 893.01% | 41.74% |
* Healthcare Sector Average
GRCE
Grace Therapeutics
2.20
-1.05
-32.31%
PYPD
PolyPid
5.10
1.60
45.71%
ALGS
Aligos Therapeutics
6.67
-3.53
-34.61%
INKT
MiNK Therapeutics
12.20
-2.70
-18.12%
CVKD
Cadrenal Therapeutics, Inc.
1.61
-10.87
-87.10%
Grace Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Grace Therapeutics Raises Capital to Advance GTx-104 Program
Positive
Aug 6, 2026
On August 4, 2026, Grace Therapeutics entered into a private placement with institutional and accredited investors to sell 4,761,904 shares of common stock at $2.10 per share, raising approximately $10 million in gross proceeds, with Craig-Hallum ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics advances dual-source manufacturing for GTx-104
Neutral
Jul 28, 2026
On July 28, 2026, Grace Therapeutics announced it had received formal minutes from an FDA Type A meeting held to discuss the Complete Response Letter issued on April 23, 2026 for its GTx-104 new drug application. The CRL focused on facility-level ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress
Neutral
Jun 18, 2026
On June 18, 2026, Grace Therapeutics updated its corporate presentation to highlight progress on GTx-104, an intravenous nimodipine designed to address limitations of long-established oral standard-of-care therapy in aneurysmal subarachnoid hemorr...
Executive/Board Changes
Grace Therapeutics VP of Clinical Operations Departs Role
Neutral
Jun 5, 2026
Grace Therapeutics, Inc. reported that Vice President of Clinical Operations Carrie D’Andrea will leave her executive role and cease to be an employee effective June 5, 2026, following board approval on June 1, 2026. She is expected to recei...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.